Financial Update: Connect Biopharma Maintains Strong Cash Position Amid Q1 Loss Connect Biopharma reported a net loss of $10.3 million for Q1 2025, or $0.19 per share, slightly deeper than last year. However, the company holds $84 million in cash, providing funding into 2027, supporting its ongoing clinical trials for rademikibart in asthma and COPD.567